Ozempic: What It Is, How It Works, and What to Know

Ozempic: What It Is, How It Works, Benefits, Side Effects, and Uses

Ozempic is a prescription medicine containing semaglutide. It is used with diet and physical activity to improve blood sugar control in adults with type 2 diabetes. In the United States, it is also approved to reduce certain cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained kidney-function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. These are specific indications—not benefits that automatically apply to everyone who takes the medicine. (FDA, 2025)

Ozempic is often discussed in connection with weight loss because semaglutide can reduce appetite and body weight. However, Ozempic is not FDA-approved in the United States specifically as a weight-management medicine. Wegovy is a separately branded semaglutide product approved for chronic weight management in eligible patients. A clinician can help determine which treatment, if any, fits a person's diagnosis, health history, and goals.

This guide explains how Ozempic works, what its approved uses are, common side effects, important warnings, and how it differs from Wegovy and Rybelsus. It is educational information, not a substitute for advice from a qualified healthcare professional.

Key Takeaways

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Its US-approved uses include improving blood sugar control in adults with type 2 diabetes and reducing specified cardiovascular and kidney risks in certain adults with type 2 diabetes. (FDA, 2025)
It is injected under the skin once weekly. The prescriber determines the dose and any increases.
Nausea, vomiting, diarrhea, constipation, and abdominal pain are among the most common adverse effects. (FDA, 2025)
Ozempic carries a boxed warning about thyroid C-cell tumors observed in rodents. It must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Do not use Ozempic for weight loss, change a dose, combine semaglutide products, or stop treatment without discussing the plan with your prescriber.

What Is Ozempic Prescribed For?

Ozempic is the brand name for a prescription injection whose active ingredient is semaglutide. It belongs to the GLP-1 receptor agonist class, which acts on pathways involved in blood glucose regulation, appetite, and digestion. In the US, its approved indications are defined in the FDA-approved prescribing information. (FDA, 2025)

Approved uses in adults with type 2 diabetes

Ozempic is approved as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events—cardiovascular death, nonfatal heart attack, or nonfatal stroke—in adults with type 2 diabetes and established cardiovascular disease. A separate indication covers reducing the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The cardiovascular and kidney indications apply to the specified patient groups, not to all users. (FDA, 2025)

Is Ozempic approved for weight loss?

Ozempic is not FDA-approved specifically for chronic weight management. Weight loss may occur during treatment, but a medicine's observed effect is not the same as an approved indication. Wegovy, another semaglutide product, is approved with reduced-calorie eating and increased physical activity for chronic weight management in eligible adults and certain pediatric patients. Wegovy also has an FDA-approved indication to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. (FDA, 2024)

A clinician may sometimes prescribe a medicine off-label, meaning for a use that is not listed in its FDA-approved indications. Off-label prescribing is a clinical decision, not a guarantee that the medicine is appropriate or safe for a particular person. Do not obtain semaglutide from unverified sellers or use someone else's prescription.

How Semaglutide Works

GLP-1 receptor activity and blood sugar

GLP-1 is a hormone involved in the body's response to food. Semaglutide activates GLP-1 receptors. In a glucose-dependent manner, this can increase insulin release when blood glucose is elevated and reduce glucagon secretion. Insulin helps move glucose out of the bloodstream, while glucagon signals the liver to release glucose. Semaglutide is not insulin and does not replace insulin when insulin therapy is medically required. (FDA, 2025)

Appetite, food intake, and digestion

Semaglutide can affect appetite-regulating pathways and may reduce hunger and food intake. It also delays gastric emptying, particularly early in treatment, which can contribute to a feeling of fullness and can affect how quickly some oral medicines are absorbed. The extent of these effects varies, and delayed stomach emptying can also contribute to digestive symptoms. (FDA, 2025)

Why Ozempic is taken once a week

Ozempic is formulated for subcutaneous injection once weekly, on the same day each week, at any time of day and with or without meals. The prescribing information allows injection into the abdomen, thigh, or upper arm. Follow the current instructions supplied with your specific pen and ask a pharmacist or prescriber if you are unsure how to use it. (FDA, 2025)

Ozempic Dosing: What to Know

The FDA-approved label describes a gradual starting schedule to help limit gastrointestinal adverse effects. The usual starting dose is 0.25 mg once weekly for four weeks, followed by 0.5 mg once weekly. Depending on the indication, response, and tolerability, a prescriber may increase the dose after at least four weeks at the current dose. The maximum recommended Ozempic dose in the cited US prescribing information is 2 mg once weekly. The 0.25 mg starting dose is an initiation dose, not a maintenance dose for glycemic control. (FDA, 2025)

This is general label information, not an individualized dosing instruction. Do not increase the dose early, take extra medicine to speed up weight loss, or adjust other diabetes medicines yourself. If you miss a dose, the label says to take it as soon as possible within five days of the missed dose; if more than five days have passed, skip it and take the next dose on the regular day. Confirm instructions against your current medication guide and ask your pharmacist if the timing is unclear. (FDA, 2025)

Potential Benefits and What the Evidence Means

Blood glucose and A1C

Ozempic can improve blood glucose control in adults with type 2 diabetes when used as prescribed alongside diet and physical activity. A1C estimates average blood glucose over roughly the previous three months, so clinicians may use A1C results alongside glucose readings, symptoms, side effects, and other health measures to assess response. The size of the response differs by person and depends on factors such as the prescribed dose, other medicines, and overall health. (FDA, 2025)

Cardiovascular and kidney risk reduction for eligible patients

Ozempic's FDA-approved cardiovascular and kidney indications apply to adults with type 2 diabetes who also have the specific conditions described in the label: established cardiovascular disease or chronic kidney disease. These indications should not be generalized to people without those conditions. A clinician can explain the expected benefit in the context of a patient's baseline risk and the rest of their treatment plan. (FDA, 2025)

Weight changes

Some people lose weight while taking Ozempic, but the amount varies and Ozempic is not the product specifically approved for chronic weight management. Evidence from a separate trial of semaglutide 2.4 mg for weight management should not be presented as a guaranteed result for Ozempic users, because the product, dose, study population, and treatment purpose differ.

In an extension of the STEP 1 trial, 327 adults without diabetes who had completed 68 weeks of semaglutide 2.4 mg or placebo were followed after treatment ended. Among the analyzed participants, the semaglutide group had lost a mean 17.3% of body weight during treatment and regained an average 11.6 percentage points during the following year. The extension analyses were exploratory and involved a subset of the original trial, so the figures should not be treated as a prediction for every patient or as direct evidence about Ozempic dosing. (Wilding et al., 2022)

Common Ozempic Side Effects

The most frequently reported adverse effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Digestive symptoms may be more noticeable when starting treatment or increasing the dose. Some people find that symptoms ease over time, but persistent, severe, or worsening symptoms should be discussed with a healthcare professional rather than simply endured. (FDA, 2025)

Practical steps to discuss with your care team

Ask whether your dose-increase schedule should be delayed if side effects are difficult to tolerate.
If nausea or fullness is an issue, consider smaller meals and stop eating when comfortably full; ask your clinician whether particular foods or meal patterns may help.
Drink fluids as tolerated, especially if vomiting or diarrhea occurs. Seek advice if you cannot keep fluids down or show signs of dehydration.
Do not take additional medicines to treat side effects without checking for interactions or suitability with a pharmacist or prescriber.

Low blood sugar

Ozempic alone has a relatively low risk of causing hypoglycemia, but the risk increases when it is used with insulin or a sulfonylurea. Symptoms can include shakiness, sweating, dizziness, confusion, a fast heartbeat, or unusual hunger. Your prescriber may need to adjust other diabetes medicines and explain how and when to check glucose. Do not reduce or stop insulin on your own. (FDA, 2025)

Important Warnings and Serious Risks

Thyroid C-cell tumors: boxed warning

Semaglutide caused thyroid C-cell tumors in rodents in studies; whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans is unknown. Ozempic is contraindicated for people with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Tell your prescriber if either applies to you. A new neck lump, persistent hoarseness, trouble swallowing, or difficulty breathing warrants medical evaluation. (FDA, 2025)

Pancreatitis and gallbladder problems

Acute pancreatitis and acute gallbladder disease, including gallstones and gallbladder inflammation, have been reported with GLP-1 receptor agonists, including semaglutide. Seek urgent medical care for severe, persistent abdominal pain—especially if it spreads to the back—or abdominal pain with repeated vomiting. Contact a healthcare professional promptly for symptoms that may indicate gallbladder disease, such as persistent upper-right abdominal pain, fever, or yellowing of the skin or eyes. (FDA, 2025)

Dehydration and kidney injury

Vomiting or diarrhea can lead to dehydration, which may contribute to acute kidney injury, particularly in people who already have kidney problems or cannot replace lost fluids. Contact your healthcare professional if you have persistent gastrointestinal symptoms, reduced urination, marked dizziness, or difficulty keeping fluids down. Do not assume that a medicine with a kidney-related approved indication is risk-free for every person with kidney disease. (FDA, 2025)

Diabetic retinopathy and vision changes

Diabetic retinopathy complications have been reported in a clinical trial, and people with a history of diabetic retinopathy may need monitoring. Tell your clinician about existing eye disease and report new or worsening vision changes promptly. (FDA, 2025)

Severe allergic reactions and procedures involving anesthesia

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Trouble breathing or swelling of the face, lips, tongue, or throat is an emergency. Ozempic's prescribing information also warns about reports of pulmonary aspiration during general anesthesia or deep sedation. Tell the healthcare team responsible for a planned operation, endoscopy, or other procedure that you take semaglutide; do not stop it or change the timing unless the treating team instructs you to do so. (FDA, 2025)

Who Should Discuss Ozempic Carefully With a Clinician?

Before treatment, tell your prescriber about your medical history, all prescription and nonprescription medicines, supplements, allergies, and any previous reactions to semaglutide. Particular topics to discuss include:

Personal or family history of MTC, or a diagnosis of MEN 2, which are contraindications.
Previous pancreatitis, gallbladder disease, severe digestive problems, or suspected gastroparesis. Ozempic is not recommended for people with severe gastroparesis.
Diabetic retinopathy or recent changes in vision.
Kidney disease or a risk of dehydration, especially if vomiting or diarrhea occurs.
Use of insulin, sulfonylureas, or other medicines that lower blood glucose.
Other medicines taken by mouth, because delayed gastric emptying may affect absorption of some oral medications.
Pregnancy, plans to become pregnant, or breastfeeding. The FDA label advises discontinuing Ozempic at least two months before a planned pregnancy because semaglutide has a long washout period. Discuss individual circumstances with your clinician.
Any planned surgery or procedure involving general anesthesia or deep sedation.

These considerations do not all mean that Ozempic is automatically unsuitable; some require individualized assessment, monitoring, or a different treatment choice. The prescribing information lists the formal contraindications and warnings. (FDA, 2025)

Ozempic vs. Wegovy vs. Rybelsus

These medicines contain semaglutide, but they have different formulations, approved uses, and dosing instructions. They should not be substituted for one another without a prescriber's direction.

Product	Form	Main US-approved role	Typical schedule
Ozempic	Injection under the skin	Type 2 diabetes; specified cardiovascular and kidney risk-reduction indications in eligible adults	Once weekly
Wegovy	Semaglutide product available as an injection; check current labeling for formulation-specific instructions	Chronic weight management in eligible patients; cardiovascular risk reduction in certain adults with overweight or obesity and established cardiovascular disease	Injection is once weekly
Rybelsus	Oral tablet	Type 2 diabetes	Once daily, following product-specific instructions

Ozempic's uses and weekly injection schedule are described in its FDA prescribing information. (FDA, 2025) The FDA announced Wegovy's cardiovascular-risk-reduction indication in 2024. (FDA, 2024) Rybelsus has its own prescribing information and administration requirements; check the current label rather than assuming its instructions match those for Ozempic. (FDA, 2025)

What Happens If You Stop Taking Ozempic?

Do not stop or restart Ozempic without discussing the plan with your prescriber, particularly if you use it to manage diabetes. Blood glucose may rise when treatment is discontinued, and your care team may need to adjust the broader diabetes plan.

Appetite and weight can also change after semaglutide treatment ends. In the STEP 1 extension, adults without diabetes who had used semaglutide 2.4 mg for weight management regained, on average, about two-thirds of their prior weight loss during the year after treatment and lifestyle intervention were stopped. Because this was an exploratory extension involving a subset of trial participants, it does not predict what will happen to every individual or to every semaglutide dose. (Wilding et al., 2022)

If you are considering stopping, ask about glucose monitoring, alternative treatments, nutrition and activity support, and a follow-up plan. Weight regain is not a personal failure; obesity and type 2 diabetes are complex conditions that may require ongoing care.

How to Decide Whether Ozempic Fits Your Treatment Plan

Clarify the treatment goal. Discuss your diagnosis, A1C and glucose goals, and whether you have cardiovascular disease or chronic kidney disease relevant to an approved indication.
Review benefits and risks. Ask how likely the expected benefits are in your circumstances, which side effects to watch for, and which symptoms require urgent care.
Review other medicines. Make sure the prescriber knows about insulin, sulfonylureas, other semaglutide products, and all oral medicines and supplements.
Agree on monitoring. Establish how progress, side effects, glucose readings, A1C, kidney status, and any eye-related concerns will be followed.
Plan for changes. Ask what to do about missed doses, illness, planned procedures, pregnancy plans, or a decision to stop treatment.

Ozempic is one option within a broader treatment plan, not a replacement for individualized diabetes care. Your clinician can compare it with other medications and nonmedication approaches based on your health priorities.

Frequently Asked Questions

What is Ozempic primarily used for?

Ozempic is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It also has specific FDA-approved cardiovascular and kidney risk-reduction indications for certain adults with type 2 diabetes. (FDA, 2025)

Does Ozempic cause weight loss?

Weight loss can occur because semaglutide may reduce appetite and food intake, but individual results vary. Ozempic is not FDA-approved specifically for chronic weight management; Wegovy is a separately branded semaglutide product approved for that purpose in eligible patients.

What are the most common side effects?

Nausea, vomiting, diarrhea, constipation, and abdominal pain are among the most common. Persistent or severe symptoms, especially those that prevent you from keeping fluids down, warrant medical advice. (FDA, 2025)

Can Ozempic and Wegovy be used together?

Do not combine Ozempic with Wegovy unless a qualified prescriber specifically directs a treatment change. Both contain semaglutide, and using duplicate products can expose you to excessive doses and additional adverse effects.

Is Ozempic a type of insulin?

No. Ozempic is a GLP-1 receptor agonist. It helps regulate glucose partly by increasing the body's insulin response when blood glucose is elevated; it is not insulin and does not replace prescribed insulin therapy.

What is the usual Ozempic dosing schedule?

The FDA label describes starting at 0.25 mg once weekly for four weeks, then increasing to 0.5 mg once weekly. Further increases may be prescribed when appropriate. Your own dose must follow your prescription and current medication instructions. (FDA, 2025)

What should I do if I want to stop Ozempic?

Talk to your prescriber first. Stopping may affect blood glucose, appetite, and body weight, so discuss monitoring and alternative treatment options before making a change.

What serious Ozempic warnings should I know about?

The medicine has a boxed warning about thyroid C-cell tumors observed in rodents and is contraindicated in people with a personal or family history of MTC or MEN 2. Other warnings include pancreatitis, gallbladder disease, dehydration-related kidney injury, serious allergic reactions, hypoglycemia with certain other diabetes medicines, and diabetic retinopathy complications. Review the current medication guide with your clinician. (FDA, 2025)

How is Rybelsus different from Ozempic?

Both contain semaglutide and are used for type 2 diabetes, but Ozempic is an injection taken weekly and Rybelsus is an oral tablet taken daily with specific administration instructions. Their doses and instructions are not interchangeable. (FDA, 2025)

Who should not take Ozempic?

Ozempic is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with MEN 2, and people with a serious hypersensitivity reaction to semaglutide or an ingredient in the product. Other health conditions may require additional caution or monitoring, so a prescriber should review your medical history. (FDA, 2025)

Conclusion

Ozempic is a once-weekly semaglutide injection used to improve blood glucose control in adults with type 2 diabetes, with additional cardiovascular and kidney risk-reduction indications for specific eligible groups. It can affect appetite and body weight, but it is not the semaglutide product specifically approved for chronic weight management. Understanding the approved uses, dosing instructions, common side effects, and serious warnings can help you have a more informed discussion with your healthcare professional.

References

U.S. Food and Drug Administration. (2025). Ozempic (semaglutide) injection: Prescribing Information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf. Used for approved indications, dosage, contraindications, warnings, adverse reactions, and administration instructions.
U.S. Food and Drug Administration. (2024, March 8). FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or. Used for Wegovy's cardiovascular-risk-reduction indication.
Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725. Full text (PubMed Central). Used for the carefully qualified discussion of weight regain after stopping semaglutide 2.4 mg used for weight management. The study is open access; the extension analyses were exploratory.
U.S. Food and Drug Administration. (2025). Rybelsus (semaglutide) tablets: Prescribing Information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051Orig1s020,213051Orig1s021lbl.pdf. Used to distinguish the oral product's formulation and product-specific instructions.